CDK8/19-IN-1 是一種有效的，選擇性的，可口服的 CDK8/19 雙重抑制劑，對 CDK8，CDK19 和 CDK9 的 IC50 值分別為 0.46 nM，0.99 nM 和 270 nM。
CDK8/19-IN-1 (52h) is a potent CDK8/19 dual inhibitor, with IC
50
s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. CDK8/19-IN-1 also weakly inhibits CDK2, with 62% inhibition at 1 μM. CDK8/19-IN-1 (1 μM) shows >50% inhibition against GSK3β, PLK1, ASK1, CK1δ, PKA, ROCK1, PKCθ, CDC7. CDK8/19-IN-1 shows K
d
s of 25, 46, 81, 86, 97, 160 and >3000 nM for CDK19, CDK8, DYRK1B, HASPIN, YSK4, HIPK1 and EPHA3, respectively. CDK8/19-IN-1 displays potent antitumor activity, with GI
50
of 0.43-2.5 nM for colon, multiple myeloma, acute myelogenous leukemia (AML), lung cancer cells.